In this study, we identified TRIM22 as a potential modulator of NF-κB signaling, by screening activity from an NF-κB-dependent transcriptional luciferase reporter construct in response to knockout of five TRIM genes overexpressed in GBM. This evidence concerns the gene TRIM22 and glioblastoma.